Clinical trials: Oligoprogression, open to volunteers
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute
Oligoprogression, Oligometastatic Disease
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
- Conditions
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- Trial name
- NCT06918951
- Testing
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Where
- Canada
- Volunteers
- 194 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
- Trial name
- SPARK (NCT06601296)
- Testing
- IMSA101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer, Oligoprogressive
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Prostate Cancer, Oligoprogressive, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- LAYOVER (NCT06101290)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, Davis
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma…
- Conditions
- Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05830058
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Oligoprogressive, Castration-Resistant Prostate Cancer
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases.
- Trial name
- NCT04838899
- Testing
- Stereotactic Body Radiation Therapy (SABR)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Non-small Cell Lung Cancer
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if…
- Trial name
- CURB2 (NCT06686771)
- Testing
- SBRT, First or second-line standard of care therapy
- Where
- 75 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Canadian Cancer Trials Group
Oligometastatic Disease
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
Most patients with metastatic cancer eventually develop resistance to systemic therapy. A subset of patients experience oligoprogression, characterized by progression at a limited number of lesions while other disease sites…
- Trial name
- NCT07333651
- Testing
- Standard-of-Care Systemic Therapy, 125I Seed Implantation
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min
Breast Cancer Invasive, Metastatic Cancer
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included.
- Conditions
- Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive
- Trial name
- COSMO (NCT05301881)
- Testing
- Surgery, Radiotherapy, Radiofrequent ablation
- Where
- 7 sites in Netherlands
- Volunteers
- 56 people
- Sponsor
- The Netherlands Cancer Institute
Non-small Cell Lung Cancer, Oligoprogressive
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
- Trial name
- OBLITERATE (NCT06103682)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Davis
OligoProgressive Metastatic Disease
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation [the removal or destruction of a body part or tissue or its function], or embolization [a…
- Trial name
- NCT06367972
- Testing
- Local Consolidation Therapy, Next-line Systemic Therapy
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- M.D. Anderson Cancer Center
Castration-resistant Prostate Cancer, Oligoprogressive
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.
- Trial name
- MEDCARE (NCT06585007)
- Testing
- Radiotherapy, metastasectomy
- Where
- Belgium
- Volunteers
- 246 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Breast Cancer, Oligoprogression
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
Recent advances in systemic therapy have facilitated improved progression-free survival (PFS) and treatment tolerability in metastatic breast cancer patients (MBC).
- Trial name
- STAR-B (NCT06489821)
- Testing
- Stereotactic body radiotherapy
- Volunteers
- 36 people
- Sponsor
- Juravinski Cancer Center
Oligometastatic Disease, Oligoprogression
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs.
- Conditions
- Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
- Trial name
- NCT05784428
- Testing
- Single fraction SABR, Multiple fraction SABR, QoL reporting alone
- Where
- 14 sites in Canada, Ireland
- Volunteers
- 598 people
- Sponsor
- Robert Olson
Ovarian Cancer Recurrent
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and…
- Trial name
- SOPRANO (NCT05990192)
- Testing
- Niraparib oral capsule, SBRT
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with…
- Trial name
- CURB-TKI (NCT06813664)
- Testing
- Radiotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy…
- Trial name
- SECURE (NCT06927635)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Systemic therapy
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto
Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy.
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
- Trial name
- OPPRESS (NCT06523673)
- Testing
- Stereotactic Body Radiotherapy, second-line systemic therapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT06260033
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Metastatic Cancer, Oligoprogressive
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
A registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin…
- Trial name
- SUPPRESS (NCT04989725)
- Testing
- Standard arm, Experimental arm
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)